Other OTC - Delayed Quote USD

Northwest Biotherapeutics, Inc. (NWBO)

0.4850 +0.0080 (+1.68%)
At close: April 26 at 3:59 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
1,932.0000
1,932.0000
1,683.0000
1,005.0000
1,291.0000
Operating Expense
57,440.0000
57,440.0000
68,864.0000
53,707.0000
87,896.0000
Operating Income
-55,508.0000
-55,508.0000
-67,181.0000
-52,702.0000
-86,605.0000
Net Non Operating Interest Income Expense
-5,241.0000
-5,241.0000
-6,068.0000
-5,011.0000
-8,544.0000
Other Income Expense
-1,850.0000
-1,850.0000
-31,783.0000
236,839.0000
-434,672.0000
Pretax Income
-62,599.0000
-62,599.0000
-105,032.0000
179,126.0000
-529,821.0000
Net Income Common Stockholders
-64,373.0000
-64,373.0000
-105,032.0000
179,126.0000
-529,821.0000
Diluted NI Available to Com Stockholders
-64,373.0000
-64,373.0000
-105,032.0000
179,126.0000
-529,821.0000
Basic EPS
-0.06
-0.06
-0.10
0.21
-0.73
Diluted EPS
-0.06
-0.06
-0.10
-0.06
-0.73
Basic Average Shares
1,119,191.0000
1,119,191.0000
1,015,852.0000
873,517.0000
725,129.0000
Diluted Average Shares
1,119,191.0000
1,119,191.0000
1,015,852.0000
1,007,869.0000
725,129.0000
Total Operating Income as Reported
-55,508.0000
-55,508.0000
-67,181.0000
-52,702.0000
-86,605.0000
Total Expenses
57,440.0000
57,440.0000
68,864.0000
53,707.0000
87,896.0000
Net Income from Continuing & Discontinued Operation
-62,599.0000
-62,599.0000
-105,032.0000
179,126.0000
-529,821.0000
Normalized Income
-60,827.0000
-60,827.0000
-73,216.0000
5,761.2200
-95,149.0000
Interest Expense
5,241.0000
5,241.0000
6,068.0000
5,011.0000
8,544.0000
Net Interest Income
-5,241.0000
-5,241.0000
-6,068.0000
-5,011.0000
-8,544.0000
EBIT
-57,358.0000
-57,358.0000
-98,964.0000
184,137.0000
-521,277.0000
EBITDA
-55,625.0000
-55,625.0000
-97,464.0000
184,723.0000
-520,852.0000
Reconciled Depreciation
1,733.0000
1,733.0000
1,500.0000
586.0000
425.0000
Net Income from Continuing Operation Net Minority Interest
-62,599.0000
-62,599.0000
-105,032.0000
179,126.0000
-529,821.0000
Total Unusual Items Excluding Goodwill
-1,772.0000
-1,772.0000
-31,816.0000
237,486.0000
-434,672.0000
Total Unusual Items
-1,772.0000
-1,772.0000
-31,816.0000
237,486.0000
-434,672.0000
Normalized EBITDA
-53,853.0000
-53,853.0000
-65,648.0000
-52,763.0000
-86,180.0000
Tax Rate for Calcs
--
--
--
0.0003
--
Tax Effect of Unusual Items
--
--
--
64,121.2200
--
12/31/2020 - 12/14/2001

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

CVM CEL-SCI Corporation
1.4400
-0.69%
 
AVXL Anavex Life Sciences Corp.
3.4400
+1.47%
 
TLSA Tiziana Life Sciences Ltd
0.7801
-8.22%
 
ANVS Annovis Bio, Inc.
18.01
+32.43%
 
ANIX Anixa Biosciences, Inc.
3.2300
+8.39%
 
ATNM Actinium Pharmaceuticals, Inc.
6.87
+4.73%
 
CTXR Citius Pharmaceuticals, Inc.
0.6648
-9.25%
 
NRXP NRx Pharmaceuticals, Inc.
3.5400
+12.74%
 
CYDY CytoDyn Inc.
0.1430
-2.05%
 
OTLK Outlook Therapeutics, Inc.
8.43
+2.93%